key: cord-0871978-m0en094s
authors: Shree, Venkatesan; En Liew, Lydia Qi; Teo, Wei Wei; Ting, Jeanette; Liew, Mei Fong
title: Potentially fatal severe brady arrythmias related to Lopinavir-Ritonavir in a COVID 19 patient
date: 2020-08-06
journal: J Microbiol Immunol Infect
DOI: 10.1016/j.jmii.2020.07.015
sha: 54b6d6eb22e4e043e8f909c99d5e2a18fd138b53
doc_id: 871978
cord_uid: m0en094s

nan

Dear Editor,

The novel coronavirus (COVID-19) outbreak was declared a global pandemic, with over 6 million people infected, and 371166 deaths worldwide. Without proven treatments for severe COVID-19, physicians have resorted to experimental therapies like Lopinavir-Ritonavir. 1, 2 We report the first case of potentially fatal bradyarrhythmias with long sinus pauses due to Lopinavir-Ritonavir.

The patient is a 67-year-old male with a history of hypertension and coronary artery disease. He tested positive for COVID-19 on day 5 of respiratory symptoms. On day 10, he deteriorated and Lopinavir 4mg/kg / Ritonavir 1mg/kg 12-hourly was initiated. His baseline electrocardiogram showed a heart rate of 84bpm, and QTc of 496ms.

On day 12, he developed moderate acute respiratory distress syndrome requiring intubation and mechanical ventilation. He was subsequently sedated with IV propofol (2-2.5mg/kg/h) and fentanyl (1-1.5mcg/kg/h).

On day 15, he developed episodes of sinus pauses, longest recorded was 3.8s with spontaneous recovery. Hours later, he developed sustained significant bradycardia (30bpm) with severe hypotension (systolic blood pressure 50mmHg) (Figures 1a, 1b) . He was given intravenous ephedrine 20mg and atropine 1200mcg, and was subsequently started on intravenous dopamine 5mcg/kg/min. Transcutaneous pacing pads were applied with a backup rate of 50bpm. A transthoracic echocardiogram showed a normal ejection fraction. Throughout the day, we observed multiple bradycardic episodes requiring backup pacing (Figure 1c ). Lopinavir-Ritonavir was discontinued.

After cessation of Lopinavir-Ritonavir, no further episodes of bradyarrhythmias were observed. Dopamine was weaned off over 48 hours, and his heart rate remained stable. He made a full recovery subsequently.

Lopinavir-Ritonavir is the most common protease inhibitor listed for investigational or compassionate use for COVID-19 in international clinical guidelines. However, current evidence on the efficacy and safety of any protease inhibitors for treating COVID-19 infection is debated. 1,2 Despite some recommendations that Lopinavir-Ritonavir should be started early 2 , there are side effects that should be weighed cautiously. 

A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19

Lopinavir/ritonavir use in Covid-19 infection: is it completely nonbeneficial?

Blockade of HERG channels by HIV protease inhibitors. The Lancet

Pacemaker channel dysfunction in a patient with sinus node disease

Transient cardiac arrhythmias related to lopinavir/ritonavir in two patients with HIV infection. Sexual health